- Home
- SKYT vs OPT Comparison
SKYT vs OPT Comparison
Compare SKYT & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYT
- OPT
- Stock Information
- Founded
- SKYT 1991
- OPT 1984
- Country
- SKYT United States
- OPT Australia
- Employees
- SKYT N/A
- OPT N/A
- Industry
- SKYT Semiconductors
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SKYT Technology
- OPT Health Care
- Exchange
- SKYT Nasdaq
- OPT Nasdaq
- Market Cap
- SKYT 560.4M
- OPT 574.0M
- IPO Year
- SKYT 2021
- OPT 2020
- Fundamental
- Price
- SKYT $11.76
- OPT $4.41
- Analyst Decision
- SKYT Strong Buy
- OPT Strong Buy
- Analyst Count
- SKYT 4
- OPT 1
- Target Price
- SKYT $12.75
- OPT $12.00
- AVG Volume (30 Days)
- SKYT 1.1M
- OPT 19.4K
- Earning Date
- SKYT 02-24-2025
- OPT 02-26-2025
- Dividend Yield
- SKYT N/A
- OPT N/A
- EPS Growth
- SKYT N/A
- OPT N/A
- EPS
- SKYT N/A
- OPT N/A
- Revenue
- SKYT $345,935,000.00
- OPT $261,859.00
- Revenue This Year
- SKYT $21.36
- OPT N/A
- Revenue Next Year
- SKYT N/A
- OPT $46,864.26
- P/E Ratio
- SKYT N/A
- OPT N/A
- Revenue Growth
- SKYT 26.89
- OPT N/A
- 52 Week Low
- SKYT $5.63
- OPT $1.79
- 52 Week High
- SKYT $19.00
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- SKYT 47.98
- OPT 66.30
- Support Level
- SKYT $11.40
- OPT $3.59
- Resistance Level
- SKYT $12.44
- OPT $3.90
- Average True Range (ATR)
- SKYT 1.08
- OPT 0.26
- MACD
- SKYT -0.44
- OPT 0.06
- Stochastic Oscillator
- SKYT 12.91
- OPT 100.00
About SKYT SkyWater Technology Inc.
SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.